Member Info for Wassatt

This is the ‘single most important factor to follow’ for the stock market! Hint: it isn’t trade wars, says Third Point’s Loeb

https://uk.finance.yahoo.com/m/21723fa5-ec86-340d-8ca2-d1dad7c4d9e6/this-is-the-‘single-most.html?.tsrc=applewf

Bond Shock May Trigger Stocks Slump, Australia's Magellan Warns

https://finance.yahoo.com/news/bond-shock-may-trigger-stocks-040636712.html?.tsrc=applewf

Asian Equities Mixed; China’s Easing Policy Remains in Focus

https://finance.yahoo.com/news/asian-equities-mixed-china-easing-044000278.html?.tsrc=applewf

Now it's time for a cuppa and await the bell...,

Babs
I thought you were getting later on parade these days..... due to transport!!

Do you think this Draw Down loan facility with MTL will see it tank then ????

Hahaha.....yeah I see your mistake now ....lol

Their final results look promising
Predicting a very good year ahead

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has acquired the global rights to Imukin® (recombinant human interferon gamma-1b) from Horizon Pharma plc ('Horizon'). Horizon will retain the rights to Actimmune® (recombinant human interferon gamma-1b) in the US, Canada and Japan.

Imukin® is licensed in 19 countries globally to reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD) and for the treatment of Severe Malignant Osteopetrosis (SMO), both considered rare conditions.

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has acquired the global rights to Imukin® (recombinant human interferon gamma-1b) from Horizon Pharma plc ('Horizon'). Horizon will retain the rights to Actimmune® (recombinant human interferon gamma-1b) in the US, Canada and Japan.

Imukin® is licensed in 19 countries globally to reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD) and for the treatment of Severe Malignant Osteopetrosis (SMO), both considered rare conditions.

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, has acquired the global rights to Imukin® (recombinant human interferon gamma-1b) from Horizon Pharma plc ('Horizon'). Horizon will retain the rights to Actimmune® (recombinant human interferon gamma-1b) in the US, Canada and Japan.

Imukin® is licensed in 19 countries globally to reduce the frequency of serious infections in patients with Chronic Granulomatous Disease (CGD) and for the treatment of Severe Malignant Osteopetrosis (SMO), both considered rare conditions.

Working capital funded...... usually a good sign

Final patient recruited in Stem Phase IIa trial

Look at today's RNS then m8

Acquisition

Interesting Arkoma option to increase % from 27 to 33

Acquired global rights
Gotta be be worth watching

There will always be sellers, there will always be buyers, they will keep themselves happy within the 25% remaining shares.
Don't forget there are others with largish holdings too
No, I don't think Odey are bothered about making a market for the SP, they are in it to make a killing in the cash cow.

Good morning all

Morning

I must admit I'm feeling that way tooo
So might climb
Nite all
ZzzZZZZzZzZzzzzZzzzzZzzzzzz